The Case for Process Validation

By Mark Land, AAHP President   The Homeopathic Pharmacopoeia of the United States says: “Dosage Forms – These, like all other conditions of homeopathic production should be governed by simplicity…

Read More

The British Homœopathic Pharmacopœia

brtsh hpus

By Eric Foxman, AAHP Secretary A quick look at its history, purpose, and contents, as well as the potential for adulteration and misbranding violations in the U.S. market. readm more…

Read More

Health Care Product Recalls

By Mark Land, AAHP President July 1, 2018 Product recalls are an important tool for manufacturers and the Food and Drug Administration (FDA) to minimize exposure to potentially harmful or…

Read More

Latest Updates to the HPUS

By Eric L. Foxman, Senior Scientist, HPCUS, AAHP secretary June 4, 2018 Of all the changes implemented by the Homeopathic Pharmacopoeia Convention of the United States (HPCUS) in the past…

Read More

AAHP Speaking Tour

By Mark Land, AAHP President April 24, 2018 Since the beginning of the year I have embarked on a tour to inform the community of AAHP’s position on the FDA’s…

Read More

The German Homeopathic Pharmacopeia

By Eric Foxman, AAHP secretary February 1, 2018 A quick look at its history, purpose and contents, as well as the potential for adulteration and misbranding violations in the United…

Read More

Prominence in Advertising and Labeling

By Mark Land, AAHP president February 1, 2018 A search under the term “prominence” yields 43 citations within Title 21 of the U.S. Code of Federal Regulations.1 Prominence appears 11…

Read More

Testing the New AAHP Disclaimer for Effectiveness

By Jeremy Kees, PhD, Professor, Marketing & Business Law and Faculty Director, Villanova University February 1, 2018 The American Association of Homeopathic Pharmacists (AAHP) enlisted my assistance in 2017 to…

Read More